Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
36.23
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
9 Health Care Stocks Whale Activity In Today's Session
↗
November 01, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
October 27, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Analyst Ratings for Ultragenyx Pharmaceutical
↗
July 29, 2022
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:
Via
Benzinga
Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance
↗
July 29, 2022
Via
Benzinga
Ultragenyx's Neurogenetic Disorder Candidate Shows Favorable Tolerability, Clinical Activity
↗
July 19, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
↗
October 13, 2022
Upgrades
Via
Benzinga
Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M
↗
July 14, 2022
Via
Benzinga
Expert Ratings for Ultragenyx Pharmaceutical
↗
May 24, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
↗
May 23, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
September 14, 2022
During Wednesday's session, 265 companies made new 52-week lows.
Via
Benzinga
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
↗
August 18, 2022
Gainers
Via
Benzinga
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
↗
August 18, 2022
Wolfspeed, Inc. (NYSE: WOLF) rose 20.7% to $103.40 in pre-market trading after the company reported better-than-expected Q4 results.
Via
Benzinga
NVIDIA, Tyson Foods, BioNTech And Some Other Big Stocks Moving Lower On Monday
↗
August 08, 2022
AMTD Digital Inc. (NYSE: HKD) dipped 21.8% to $563.71 on possible profit taking after the stock surged over the last few trading days.
Via
Benzinga
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
July 29, 2022
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:
Via
Benzinga
Recap: Ultragenyx Pharmaceutical Q2 Earnings
↗
July 28, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
↗
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
↗
August 01, 2022
Upgrades
Via
Benzinga
Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees 'Viable Path Forward"
↗
July 19, 2022
Via
Benzinga
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
↗
July 19, 2022
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.
Via
Benzinga
Earnings Scheduled For July 28, 2022
↗
July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter.
Via
Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
↗
July 20, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 19, 2022
Via
Benzinga
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
↗
July 19, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.
Via
Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
↗
July 19, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue...
Via
Benzinga
Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June
↗
July 19, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday.
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
↗
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
↗
July 18, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...
Via
Benzinga
What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
July 01, 2022
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:
Via
Benzinga
Netflix To $210? Here's The Biggest Price Target Changes For Friday
↗
July 01, 2022
Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.